Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

ATLANTA, January 3 /PRNewswire/ --

Global Payments Inc. (NYSE: GPN) today announced results for its second quarter ended November 30, 2007. For the second quarter, revenue grew 18 percent to US$308.8 million compared to US$260.7 million in the prior year. Excluding the impact of current period restructuring charges, diluted earnings per share grew 14 percent to US$0.48 compared to US$0.42 in the prior year quarter.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010221/ATW031LOGO )

LUGANO, Switzerland, January 3 /PRNewswire/ -- Helsinn Healthcare S.A., Switzerland, a privately owned pharmaceutical group and its partner, MGI Pharma (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that a supplemental New Drug Application (sNDA) for Aloxi(R) (palonosetron hydrochloride) Capsules for oral administration was accepted for filing by the U.S. Food and Drug Administration (FDA). Aloxi Injection is approved by the FDA for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and for the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

CAMBRIDGE, Massachusetts, January 3 /PRNewswire/ --

Mersana, a cancer therapeutics company, announced today the appointment of C. Boyd Clarke as Chairman of the Company's Board of Directors. Mr. Clarke is a senior biotechnology and pharmaceutical executive with a significant record of accomplishment over a 30-year industry career.

FREMONT, California, January 3 /PRNewswire/ --

- USB Drives Have Capacity to Hold Over 16 Full-Length High-Definition Movies or an Entire Season of a TV Series

Corsair(R) http://www.corsair.com, a worldwide leader in high performance computer and flash memory products, announced today that it is expanding its Flash Voyager and Flash Survivor USB family lines with new 32GB capacity offerings. The new Corsair 32GB Flash Voyager and Flash Survivor USB drives will be debuted at the Consumer Electronics Show 2008 (CES) next week in Las Vegas in the Corsair Suite at the Wynn Hotel and at Showstoppers CES 2008.

Ultimate Solution for Storing, Transporting & Backing-up Critical Data

BOSTON and CAMBRIDGE, England, January 3 /PRNewswire/ --

- ZigBee technology connects people with their homes via the Internet and mobile phones

AlertMe.com, provider of people-friendly home security, has teamed up with Ember to make it easy for people, wherever they may be, to keep a close eye on their homes by combining ZigBee wireless technology, the Internet and mobile phone networks.